In the case-control study nested within the screening arm of the PLCO, IGF-1 levels were not associated with prostate cancer risk [23], not giving credence to the hypothesized link between IGF-1 and prostate cancer in our study population. The gene discussed is IGF1; the disease is prostate carcinoma.